Join Kerem Shalom of Concord online for “New Therapies for Alzheimer’s Disease: How Well Do They Work and at What Price?” with Dr. David, Chief Medical Officer for the Institute for Clinical and Economic Review at Harvard Medical School
Despite medical breakthroughs in the treatment of many serious conditions, Alzheimer’s Disease remains relatively elusive, with daunting consequences for patients and their families. Earlier this year, the Food and Drug Administration (FDA) approved a new Alzheimer’s drug, Leqembi, that may modestly slow the pace of cognitive decline but with some risks and at a considerable cost.
Why is Alzheimer’s Disease (AD) such a challenge to treat? How does the FDA go about deciding whether to approve a drug? How does Leqembi compare to other drug therapies for AD? How much better is a new treatment at extending or improving patients’ lives? How do you weigh effectiveness against cost and arrive at a fair price? Dr. Rind, recently quoted in The New York Times, pointed out that “it is particularly important that new therapies be priced in line with their value to patients.” These are a few of the questions that will be addressed by Dr. David Rind in his upcoming L.E.D. talk.
Dr. Rind leads teams that analyze the effectiveness and value of drugs and medical services. Dr. Rind also works as an academic primary care physician at the Beth Israel and Deaconess Medical Center, supervising residents in internal medicine.
Join us to learn about the decades-long search for new Alzheimer’s Disease treatments and the progress that is being made, as well as the ongoing efforts to achieve cost-effectiveness for patients.+ More... - Less...
* Registration closes on May 5th
659 Elm St
Concord, MA 01742
CJP provides the above links concerning third-party events for your convenience only. CJP has no control over the content of the linked-to websites or events they describe, and accepts no responsibility for the websites, including any advertising or products or services on or available from such sites, or for any loss or damage that may arise from your attending, or registering to attend, the described events. If you decide to access any of the third-party websites linked to below, you do so entirely at your own risk and subject to the terms and conditions of use for such websites and event attendance. CJP is not responsible or liable to you or any third party for the content or accuracy of any materials provided by any third parties. All statements and/or opinions expressed in the linked-to materials or at the described events, and all commentary, articles and other content provided at the third-party websites or at the events, are solely the opinions and the responsibility of the persons or entities operating the linked-to websites and events. The inclusion of any link on this website does not imply that CJP endorses the described event, or the linked-to website or its operator. MORE